Repository logo
  • Log In
    Log in via Symplectic to deposit your publication(s).
Repository logo
  • Communities & Collections
  • Research Outputs
  • Statistics
  • Log In
    Log in via Symplectic to deposit your publication(s).
  1. Home
  2. Faculty of Medicine
  3. Faculty of Medicine
  4. Comparison of the Utility of Cocaine- and Amphetamine-Regulated Transcript (CART), Chromogranin A, and Chromogranin B in Neuroendocrine Tumor Diagnosis and Assessment of Disease Progression
 
  • Details
Comparison of the Utility of Cocaine- and Amphetamine-Regulated Transcript (CART), Chromogranin A, and Chromogranin B in Neuroendocrine Tumor Diagnosis and Assessment of Disease Progression
File(s)
jc%2E2014-3640.pdf (187.64 KB)
Published version
Author(s)
Ramachandran, R
Bech, P
Murphy, KG
Caplin, ME
Patel, M
more
Type
Journal Article
Date Issued
2015-01-09
Date Acceptance
2015-02-04
Citation
Journal of Clinical Endocrinology & Metabolism, 2015, 100 (4), pp.1520-1528
URI
http://hdl.handle.net/10044/1/23646
DOI
https://www.dx.doi.org/10.1210/jc.2014-3640
ISSN
1945-7197
Publisher
Endocrine Society
Start Page
1520
End Page
1528
Journal / Book Title
Journal of Clinical Endocrinology & Metabolism
Volume
100
Issue
4
Copyright Statement
© 2015 by the Endocrine Society
License URL
http://www.rioxx.net/licenses/all-rights-reserved
Subjects
Science & Technology
Life Sciences & Biomedicine
Endocrinology & Metabolism
CLINICAL-MANIFESTATIONS
CARCINOID-TUMORS
ENDOCRINE TUMORS
PHEOCHROMOCYTOMA
PLASMA
PEPTIDE
NEOPLASIA
MARKERS
IMMUNOREACTIVITY
PARAGANGLIOMAS
Publication Status
Published
About
Spiral Depositing with Spiral Publishing with Spiral Symplectic
Contact us
Open access team Report an issue
Other Services
Scholarly Communications Library Services
logo

Imperial College London

South Kensington Campus

London SW7 2AZ, UK

tel: +44 (0)20 7589 5111

Accessibility Modern slavery statement Cookie Policy

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback